Will SpaceX Stock Double Anytime Soon? No -- but These 3 Stocks Could

1 hour ago 4

Keith Speights, The Motley Fool

Mon, June 29, 2026 astatine 4:04 AM CDT 5 min read

Even aft its crisp pullback, Space Exploration Technologies' (NASDAQ: SPCX) marketplace headdress inactive hovers astir $2 trillion. That's an astronomical (no pun intended) valuation for a institution that generated gross of $18.7 cardinal past twelvemonth and posted a nonaccomplishment of astir $5 billion.

Could SpaceX treble anytime soon? It's highly unlikely. Maybe implicit a agelong play of time, the institution volition unfastened up breathtaking caller markets that could pb to its stock terms gaining 100% oregon more. However, its premium pricing and the prospects of near-term insider selling aft the lockup play expires contiguous important hurdles to the banal doubling implicit the adjacent 2 oregon 3 years.

Missed Nvidia successful 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" awesome flashed for a little-known chipmaker called Nvidia. For the archetypal clip successful years, that aforesaid "Total Conviction" awesome is flashing for a institution 1/100th the size of Nvidia. Continue »

Investors who privation explosive upside don't request to stake connected subject fabrication valuations. Here are 3 stocks that person realistic paths to doubling comparatively quickly.

A manus holding a pen pointing to a airy burst adjacent to a drafting of a rocket, lines ascending upward, and tiny icons.

1. ADMA Biologics

Unlike SpaceX, ADMA Biologics (NASDAQ: ADMA) is already profitable. And its net are growing. The institution posted nett income of $407 cardinal successful the archetypal quarter, up 22% twelvemonth implicit year.

ADMA markets 3 approved products, each plasma-derived immunoglobulin (IG) therapies. Asceniv is its flagship product, generating astir 86% of full revenue. It was approved by the U.S. Food and Drug Administration (FDA) successful 2019 for treating superior humoral immunodeficiency, a radical of familial disorders successful which the body's immune strategy can't marque capable antibodies, called immunoglobulins, to support against infections.

The statement analysts' 12-month terms people for this biotech banal is astir precisely treble the existent stock price. Raymond James (NYSE: RJF) precocious initiated sum of ADMA Biologics with a bargain proposal and a terms people that implies imaginable upside of astir 140%.

What's down Wall Street's optimism astir ADMA? For 1 thing, the institution has captured lone astir 4% of its full addressable marketplace truthful far. That marketplace is expected to turn astatine a compound yearly complaint of 10% done 2033. ADMA has besides developed exertion that delivers IG accumulation yields 20% oregon much higher with the aforesaid quantities of plasma, which should boost some gross and earnings.

2. EyePoint Pharmaceuticals

EyePoint Pharmaceuticals (NASDAQ: EYPT) and SpaceX stock astatine slightest 2 things successful common. Both stocks are up astir the aforesaid percent twelvemonth to date. Both companies are losing money. But EyePoint has a amended excuse for its deficiency of profitability: it doesn't yet person an approved product.

Read Entire Article